Does Venue Type Matter for HIV-Related Risk Behavior in Urban Adolescent and Young Adult Men Who Have Sex With Men?

Citation: Arrington-Sanders R, Fields E, Greenberg L, Henry-Reid L, Stines S, Korelitz J, Kapogiannis B, Ellen J, Boyer CB, and the Adolescent Medicine Trials Network for HIV/AIDS Interventions. Does venue type matter for HIV-related risk behavior in urban adolescent and young adult men who have sex with men? Youth Soc. 2019 Aug;51(8). https://doi.org/10.1177/0044118X17723655

Access full article:

https://journals.sagepub.com/doi/10.1177/0044118X17723655

Venue-based strategies offer effective means of targeting men who have sex with men. Few studies have sought to focus on where younger men congregate and understand risk behaviors that may occur at lower (i.e., community centers) versus higher risk venues. Data from 1,311 young men who have sex with men (YMSM) aged 12- to 24-years-old recruited from publicly accessible venues was used to examine the association between venue type (bar/club, community center, mixed [adjacent to bar/club, including parking lot/alley]) and HIV-related risk factors. YMSM recruited from community venues were more likely than those from bars/clubs to report more partners in last year, receive money in exchange for sex, and to be tested for HIV in prior 6 months, whereas YMSM from mixed-use venues were more likely to have ever received money in exchange for sex, and injected drugs. Community and mixed venues may be key access points for YMSM.

Categories

CRS
Topics

Clinical Trials

P1078: A Phase IV Randomized Double-Blind Placebo-Controlled...

P1078 is a Phase IV, randomized, double-blind, placebo-controlled study of HIV-infected pregnant women and the infants born to...

Read More

P1077FF: Formula Feeding Version of the PROMISE Study...

1077FF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More

A5350: Effects of Visbiome Extra Strength on Gut Microbiome...

Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...

Read More

P2026: Pharmacokinetic Properties of Antiretroviral and...

IMPAACT P1026s, the predecessor of this study, was first approved in 2003. P1026s enrolled over 1000 pregnant/postpartum women,...

Read More

A5253: Sensitivity and Specificity of Mycobacterium...

An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...

Read More